People · Operator
Named in public records as an officer, director or promoter · active 2015–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Akouos, Inc. | — | Biotechnology | Series D+ | $137.7M | $4.3B | 2018 |
| Homology Medicines, Inc. | — | Pharmaceuticals | Series C | $127.1M | $2.9B | 2015 |
Arthur Tzianabos at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Arthur Tzianabos on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kush Parmar | 2 | 10 |
| Steven Gillis | 1 | 23 |
| Ed Mathers | 1 | 11 |
| Cameron Wheeler | 1 | 9 |
| Chris Smith | 1 | 7 |
| Brad Smith | 1 | 6 |
| Heather Preston | 1 | 6 |
| Vicki Sato | 1 | 6 |
| Paul Stone | 1 | 5 |
| Mahendra Shah | 1 | 5 |
| Richard Gregory | 1 | 2 |
| Albert Seymour | 1 | 2 |
| Karoline Shair | 1 | 1 |
| Aninda Katragadda | 1 | 1 |
| Emmanuel Simons | 1 | 1 |
| Siyamak Rasty | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.